scholarly journals Cost-Effectiveness of Afatinib, Erlotinib, and Cisplatin/Pemetrexed for First-Line Treatment of Metastatic Egfr-Mutation Positive Non-Small Cell Lung Cancer

2014 ◽  
Vol 17 (3) ◽  
pp. A84
Author(s):  
J. Ting ◽  
T. Ho ◽  
P. Xiang ◽  
M. Abdel-Sattar ◽  
A. Sugay ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cost Effectiveness ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Egfr Mutation ◽  
Small Cell ◽  
Line Treatment ◽  
Small Cell Lung ◽  
First Line ◽  
First Line Treatment

scholarly journals Cost-effectiveness of Osimertinib in the First-Line Treatment of Patients WithEGFR-Mutated Advanced Non–Small Cell Lung Cancer

JAMA Oncology ◽  
2018 ◽  
Vol 4 (8) ◽  
pp. 1080 ◽  
Author(s):  
Pedro N. Aguiar ◽  
Benjamin Haaland ◽  
Wungki Park ◽  
Pui San Tan ◽  
Auro del Giglio ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cost Effectiveness ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Line Treatment ◽  
Small Cell Lung ◽  
First Line ◽  
First Line Treatment
Sign in / Sign up

Export Citation Format

Share Document